Anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab, ranibizumab, and aflibercept have been shown to reduce CRVO-related ocular morbidity via improvement in visual acuity and reduction in macular edema [4–7]. The gene discussed is VEGFA; the disease is macular retinal edema.